These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36463214)

  • 21. Nurse Practitioner-Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial.
    Khati A; Altice FL; Vlahov D; Eger WH; Lee J; Bohonnon T; Wickersham JA; Maviglia F; Copenhaver N; Shrestha R
    JMIR Res Protoc; 2022 Oct; 11(10):e42585. PubMed ID: 36222826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
    Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
    Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
    [No Abstract]   [Full Text] [Related]  

  • 23. Factors associated with perceived ease of access to syringes in Appalachian North Carolina.
    Carpenter DM; Zule WA; Hennessy CM; Evon DM; Hurt CB; Ostrach B
    J Rural Health; 2023 Jan; 39(1):212-222. PubMed ID: 35819251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
    Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
    Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
    Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
    Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center.
    Lai S; Li E; Silverio A; DeBates R; Kelly EL; Weinstein LC
    Subst Abus; 2021; 42(4):858-864. PubMed ID: 33492204
    [No Abstract]   [Full Text] [Related]  

  • 27. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
    Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
    Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV serostatus and injection sharing practices among those who obtain syringes from pharmacies and directly and indirectly from syringe services programs in rural New England.
    Romo E; Rudolph AE; Stopka TJ; Wang B; Jesdale BM; Friedmann PD
    Addict Sci Clin Pract; 2023 Jan; 18(1):2. PubMed ID: 36597153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.
    Bazzi AR; Shaw LC; Biello KB; Vahey S; Brody JK
    J Gen Intern Med; 2023 Mar; 38(4):913-921. PubMed ID: 35614171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Hershow RB; Gonzalez M; Costenbader E; Zule W; Golin C; Brinkley-Rubinstein L
    AIDS Educ Prev; 2019 Aug; 31(4):363-379. PubMed ID: 31361517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of Injection-Related Risk Behaviors After Emergency Implementation of a Syringe Services Program During an HIV Outbreak.
    Patel MR; Foote C; Duwve J; Chapman E; Combs B; Fry A; Hall P; Roseberry J; Brooks JT; Broz D
    J Acquir Immune Defic Syndr; 2018 Apr; 77(4):373-382. PubMed ID: 29271829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Were Needles Everywhere?: Differing Views on Syringe Waste and Disposal Associated With Needs-Based Syringe Services Programs Among Community Partners and Persons Who Inject Drugs.
    Hershow RB; Love Pieczykolan L; Worthington N; Adams M; McDonald R; Wilson S; McBee S; Balleydier S; Curran KG
    Subst Use Misuse; 2024; 59(8):1174-1181. PubMed ID: 38509704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals.
    Mistler CB; Curley CM; Rosen AO; El-Krab R; Wickersham JA; Copenhaver MM; Khati A; Shrestha R
    J Community Health; 2021 Oct; 46(5):960-966. PubMed ID: 33770334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
    Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
    Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Associated with Sterile Syringe Acquisition among People Who Inject Drugs in West Virginia.
    Allen ST; Mazhnaya A; O'Rourke A; White RH; Wedlock P; Grieb SM; Kilkenny ME; Walls M; Sherman SG
    Subst Use Misuse; 2021; 56(12):1776-1784. PubMed ID: 34311667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation and first-year operating costs of an academic medical center-based syringe services program.
    Bartholomew TS; Patel H; McCollister K; Feaster DJ; Tookes HE
    Harm Reduct J; 2021 Nov; 18(1):116. PubMed ID: 34798887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.
    Shrestha R; Altice FL; Karki P; Copenhaver MM
    AIDS Behav; 2018 Aug; 22(8):2640-2649. PubMed ID: 29582199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
    AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
    Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
    Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Relationship Between Polysubstance Injection Drug Use, HIV Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (PrEP) Among People Who Inject Drugs in Rural West Virginia.
    Schneider KE; White RH; Musci RJ; O'Rourke A; Kilkenny ME; Sherman SG; Allen ST
    J Stud Alcohol Drugs; 2020 Nov; 81(6):740-749. PubMed ID: 33308403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.